All In Biotech

NDA 050804 · Bausch and Lomb

Zylet

Loteprednol Etabonate, Tobramycin · Ophthalmic · Aminoglycoside Antibacterial

Last checked: Nov 19, 2026Latest source record: Oct 25, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Dec 14, 2004

Approved uses

2

Original approval plus efficacy supplements

Registered trials

63

16 Phase 3, 0 recruiting

FAERS reports

400

116 serious, 9 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 20, 2026.

Loteprednol Etabonate and Tobramycin Ophthalmic Suspension 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. Loteprednol...

Mechanism: Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins...

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZYLET · LOTEPREDNOL ETABONATE 0.5%; TOBRAMYCIN 0.3% · SUSPENSION/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Loteprednol Etabonate" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain49
  • ocular hyperaemia48
  • eye irritation47
  • drug ineffective41
  • vision blurred31
  • headache30
  • lacrimation increased28
  • eye pruritus21
  • chronic kidney disease20
  • eye swelling19
  • condition aggravated18
  • drug hypersensitivity18

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200724
200818
20094
201026
201124
201220
20137
20148
201520
201624
201732
201839
201956
202022
202122
202226
20239
20246
202510
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zylet (Tobramycin/Lotepred Etab)

2024 spending

$3.1M

Beneficiaries

5,598

8,050 claims

Per beneficiary

$557

$63.61 per unit

View as table
YearSpending
2020$3,398,226
2021$3,490,438
2022$3,812,357
2023$3,777,050
2024$3,120,370

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 57 on PubMed

Sponsor: Bausch and Lomb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.